

(19)  **Canadian
Intellectual Property
Office**

An Agency of
Industry Canada

**Office de la Propriété
Intellectuelle
du Canada**

Un organisme
d'Industrie Canada

(11) **CA 2 362 906** (13) **A1**

(40) 31.08.2000
(43) 31.08.2000

(12)

(21) 2 362 906

(22) 22.02.2000

(51) Int. Cl.⁷: **C12N 15/12, A61K 48/00,
C12P 21/02, C07H 21/04,
C12N 5/06, C12N 5/10,
C12N 1/21, G01N 33/53,
C12N 15/63, C07K 14/705**

(85) 21.08.2001

(86) PCT/US00/04413

(87) WO00/50562

(30) 09/255,376 US 22.02.1999
09/387,699 US 13.08.1999

(71) **SYNAPTIC PHARMACEUTICAL CORPORATION,
215 College Road, PARAMUS, XX (US).**

**BONINI, JAMES A. (US).
BOROWSKY, BETH E. (US).
ADHAM, NIKA (US).
THOMPSON, THELMA O. (US).
BOYLE, NOEL (US).**

(72)

(74) **SWABEY OGILVY RENAULT**

(54) ADN CODANT LE RECEPTEUR SNORF25

(54) DNA ENCODING SNORF25 RECEPTOR

(57)

This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2362906 A1 2000/08/31

(21) 2 362 906

(12) DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2000/02/22
(87) Date publication PCT/PCT Publication Date: 2000/08/31
(85) Entrée phase nationale/National Entry: 2001/08/21
(86) N° demande PCT/PCT Application No.: US 2000/004413
(87) N° publication PCT/PCT Publication No.: 2000/050562
(30) Priorités/Priorities: 1999/02/22 (09/255,376) US;
1999/08/13 (09/387,699) US

(51) Cl.Int.⁷/Int.Cl.⁷ C12N 15/12, A61K 48/00, C07K 14/705,
C12N 15/63, C07H 21/04, C12P 21/02, C12N 1/21,
C12N 5/10, C12N 5/06, G01N 33/53

(71) Demandeur/Applicant:
SYNAPTIC PHARMACEUTICAL CORPORATION, US

(72) Inventeurs/Inventors:
THOMPSON, THELMA O., US;
BOYLE, NOEL, US;
BONINI, JAMES A., US;
ADHAM, NIKA, US;
BOROWSKY, BETH E., US

(74) Agent: SWABEY OGILVY RENAULT

(54) Titre : ADN CODANT LE RECEPTEUR SNORF25
(54) Title: DNA ENCODING SNORF25 RECEPTOR

(57) Abrégé/Abstract:

This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.

Canada

<http://opic.gc.ca> • Ottawa-Hull K1A 0C9 • <http://cipo.gc.ca>

OPIC • CIPU 191

OPIC



CIPU

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
31 August 2000 (31.08.2000)

PCT

(10) International Publication Number
WO 00/50562 A3

- (51) International Patent Classification⁷: C07K 14/705, C07H 21/04, C12N 15/63, I/21, C12P 21/02, G01N 33/53
- (74) Agent: WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).
- (21) International Application Number: PCT/US00/04413
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 22 February 2000 (22.02.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/255,376 22 February 1999 (22.02.1999) US
09/387,699 13 August 1999 (13.08.1999) US
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant: SYNAPTIC PHARMACEUTICAL CORPORATION [US/US]; 215 College Road, Paramus, NJ 07652-1431 (US).
- Published:
— With international search report.
- (72) Inventors: BONINI, James, A.; 80 Manito Avenue, Oakland, NJ 07436 (US). BOROWSKY, Beth, E.; 218 Park Street, Montclair, NJ 07042 (US). ADHAM, Nika; 301 Mastin Place, Ridgewood, NJ 07450 (US). BOYLE, Noel; 369 Edgewater Road, Apt. 2, Cliffside Park, NJ 07010 (US). THOMPSON, Thelma, O.; 77 Brook Avenue, Apt. G20, Passaic Park, NJ 07055 (US).
- (88) Date of publication of the international search report:
14 December 2000
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/50562 A3

(54) Title: DNA ENCODING SNORF25 RECEPTOR

(57) Abstract: This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.

All-trans-retinal is critical for the synthesis of rhodopsin in retinal cells, where it plays a key role in the visual system. All-trans-retinal can also be converted to all-trans-retinoic acid (ATRA) by aldehyde dehydrogenase and
5 oxidase in other cell types (Bowman, W.C. and Rand, M.J., 1980).

Historically, ATRA and the other active metabolites of vitamin A, 9-cis-retinoic acid (9CRA), were thought to only
10 mediate their cellular effects through the action of nuclear retinoic acid receptors (RAR α , β , γ) and retinoid X receptors (RXR α , β , γ) (Mangelsdorf, D.J., et al, 1994). These receptors are members of a superfamily of ligand-dependent transcription factors, which include the vitamin D receptor
15 (VDR), thyroid hormone receptor (TR), and peroxisome proliferator activator receptors (PPAR). They form heterodimers and homodimers that bind to DNA response elements in the absence of ligand. In response to ligand binding the dimer changes conformation which leads to
20 transactivation and regulation of transcription of a set(s) of cell type-specific genes (Mangelsdorf, D.J., et al, 1994; Hofman, C. and Eichele, G., 1994; and Gudas, L.J. et al, 1994).

25 Since retinoic acid produces a wide variety of biological effects, it is not surprising that it is proposed to play an important role in various physiological and pathophysiological processes. Retinoids control critical physiological events including cell growth, differentiation,
30 reproduction, metabolism, and hematopoiesis in a wide variety of tissues. At a cellular level, retinoids are capable of inhibiting cell proliferation, inducing differentiation, and inducing apoptosis (Breitman, T. et al, 1980; Sporn, M. and Roberts, A., 1984, and Martin, S., et al, 1990). These
35 diverse effects of retinoid treatment prompted a series of investigations evaluating retinoids for cancer chemotherapy as well as cancer chemoprevention. Clinically, retinoids are